Category Archives: Health Care & FDA

Subscribe to Health Care & FDA RSS Feed

GT Attorneys in Tel Aviv and Other GT Offices Represent Medical Tech Company in $280M Deal

A Greenberg Traurig team of attorneys in Tel Aviv, Fort Lauderdale, Miami, Boston, and New York recently represented BioTelemetry Inc., a publicly traded company based in Pennsylvania, in its $280 million purchase of Switzerland’s LifeWatch AG, a health care technology company. LifeWatch AG began its way as an Israeli entity in the 1990s and became … Continue Reading

Health Care & FDA Practice Bulletin No. 5

Welcome to Greenberg Traurig’s Health Care & FDA Practice Bulletin, a collection of timely articles written by our attorneys that are focused on significant developments in health and FDA law. The topics in this issue include the Affordable Care Act, health care fraud and abuse, regulatory updates, FDA news, other health care topics, and upcoming … Continue Reading

GT Events during the 2016 JPMorgan Healthcare Conference & the 9th Annual OneMedForum in San Francisco

Innovation and progress are core ingredients in today’s financial ecosystem, especially in the fields of health care and life sciences.  Greenberg Traurig has a renowned healthcare practice, serving many clients in Israel and abroad.  Greenberg Traurig will be hosting two events in January during the 2016 JPMorgan Healthcare Conference and the 9th Annual OneMedForum in … Continue Reading

Greenberg Traurig Philadelphia Hosts Israeli Digital Health Summit Reception

Greenberg Traurig was pleased to play a key role in the recent Israeli Digital Health Summit in Philadelphia.  GT hosted a reception for the Israeli companies, investors and other guests and conducted a workshop for the Israeli companies. David Gitlin, a corporate shareholder and co-lead of the Emerging Tech Group, provided guidance on the investment … Continue Reading

Draft Guidances Propose Reduced FDA Oversight of General Wellness Products and Medical Device Accessories

Decisions by the U.S. Food and Drug Administration (FDA) have a tremendous impact on Israeli-based medical and pharmaceutical companies that manufacture products that are marketed and sold in the United States and around the world. On Jan. 20, 2015, the FDA issued two anticipated draft guidance documents proposing reduced FDA oversight of two types of … Continue Reading
LexBlog